Amid multiple states reporting a shortage of COVID-19 vaccine, Serum Institute and Bharat Biotech have submitted to the Centre their production plan for the next four months, informing they can ramp it up to 10 crore and 7.8 crore doses respectively by August, official sources said on Wednesday
URL copied
Bharat Biotech s Covaxin approved for phase 2/3 trials on children
The Drugs Controller General of India (DGCI) has approved Bharat Biotech s COVID-19 vaccine
Covaxin for phase II/III clinical trial on those aged between two to 18 years. The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur. In the trial, the vaccine will be given by intramuscular route in two doses at day 0 and day 28. The DCGI, after careful examination, has accepted the recommendation of Subject Expert Committee and accorded permission to conduct the Phase II/III clinical trial of Covaxin in the age group 2 to 18 years, to its manufacturer Bharat Biotech, the government said in a press note.
Bharat Biotech slashes Covaxin’s price for States to ₹400 per dose
April 29, 2021
Earlier, the Hyderabad-based company had pegged its vaccine price at ₹600 per dose for States and ₹150 for the Centre
Bowing to pressure from various quarters, Bharat Biotech on Thursday slashed price of its Covid-19 vaccine, Covaxin, to ₹400 per dose.
Previously, the Hyderabad-based company pegged its vaccine price at ₹600 per dose for States and ₹150 for the Centre.
For private hospitals, it will be sold at ₹1,200 per shot.
‘’Recognising the enormous challenges to the public healthcare system, we have made Covaxin available to State governments at a price of ₹400/dose,” the company said in a statement.
After Serum, Bharat Biotech cuts vaccine price for states to Rs 400 per dose
The company is deeply concerned with the critical pandemic circumstances that India is facing at this time, it added.
Share Via Email
| A+A A- By PTI
NEW DELHI: Bharat Biotech on Thursday announced a cut in the price of its COVID-19 vaccine Covaxin it plans to sell to the states to Rs 400 per dose from the earlier Rs 600.
This follows widespread criticism of its pricing policy as it sold Covaxin to the central government at Rs 150 per dose.
The announcement came a day after Serum Institute of India (SII) slashed the price of its COVID-19 vaccine Covishield to Rs 300 per dose from the earlier Rs 400 for state governments.
Synopsis
After the current spike has peaked, people will still need to be inoculated at a rapid pace to flatten the curve and avert a third buildup. And that’s when the folly of charging Rs 600 or Rs 1,200 for a life-saving vaccine, in a country where the working class was struggling to buy Rs 5 biscuits even before the pandemic, may become clear.
A vaccine queue in Mumbai. The world’s biggest democracy can’t shut anyone out of the market for vaccines.
After a tightly centralised vaccination drive that has delivered the required two shots to less than 2% of the population, India is opening up its inoculation strategy in the middle of a raging pandemic. Can the new approach flatten the curve?